1. CMPS will participate in a fireside chat on July 14, 2025. 2. The event features Patrick Trucchio of HC Wainwright as host. 3. COMP360, CMPS's treatment, has FDA Breakthrough Therapy designation. 4. CMPS aims to innovate mental health treatment for serious conditions.
Management's participation in the fireside chat could gain positive investor interest, similar to past events that positively impacted share prices.
The chat involves key insights into CMPS's strategic direction and drug development, which could drive stock performance.
The upcoming chat on July 14, 2025, is likely to generate immediate investor interest, similar to previous announcements that prompted quick market movements.
NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat with Patrick Trucchio, Managing Director Equity Research at HC Wainwright at 8:00 am ET on July 14th, 2025.
Management will participate in a fireside chat with Patrick Trucchio, analyst at HC Wainwright at 8:00 am ET on July 14th, 2025
Share
A live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.
About Compass Pathways
Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 synthetic psilocybin treatment, potentially a first in class treatment. COMP360 has Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD).
Compass is headquartered in London, UK, with offices in New York in the U.S. We envision a world where mental health means not just the absence of illness but the ability to thrive.